Foresee Pharmaceuticals names new senior vice president of Pharmaceutics and Manufacturing.
M2 PHARMA-November 16, 2018-Foresee Pharmaceuticals names new senior vice president of Pharmaceutics and Manufacturing
(C)2018 M2 COMMUNICATIONS
Foresee Pharmaceuticals Co Ltd (6576.TWO), a Taiwan and US-based biopharmaceutical company, announced yesterday that it has named Dr Thomas Weitao Sun as its new senior vice president of Pharmaceutics and Manufacturing.
Dr Sun is an executive with more than 20 years of experience in all aspects of pharmaceutical development, from discovery pharmaceutics to manufacturing and supply chain management for phases one to three studies, leading and playing key roles in the advancement of 14 new chemical entities into clinical studies. Most recently he was the vice president of Nonclinical Development at Nuredis Inc, and was in the leading position for medicinal chemistry, CMC and nonclinical development. Prior to Nuredis, Dr Sun was a co-inventor of fostamatinib and was the vice president of Pharmaceutics and Manufacturing at Rigel Pharmaceuticals Inc where he played a key role in the development, the NDA filing and commercial planning of Tavalisse(R).
Dr Ben Chien, chairman of Foresee, said, 'The expertise, knowledge and experience that Dr Sun brings to Foresee will further strengthen our capability in CMC and commercial planning strategies. With FP-001, LIMS 50mg ready for NDA filing and LIMS 25mg soon to complete phase 3 trial in November 2018, the timely addition of Dr Sun to our strong team will significantly enhance our vision to become a world class global pharmaceutical company to deliver comfort, compliance, convenience and cure to better patients' lives. We are very excited to have Dr Sun in the leadership team.'
((Comments on this story may be sent to firstname.lastname@example.org))